Therapy News and Research

RSS

Enzalutamide has added benefit for men with castration-resistant prostate cancer at high risk of metastasis

In 2018 and 2019, the German Institute for Quality and Efficiency in Health Care already investigated whether the drug enzalutamide has an advantage in comparison with the appropriate comparator therapy, i.e. in comparison with watchful waiting while maintaining ongoing conventional androgen deprivation therapy (ADT), for adult men with high-risk non-metastatic castration-resistant prostate cancer.

19 Aug 2020

Microbial diversity can improve treatment for cancer patients

Physicians at City of Hope, working in collaboration with scientists at Translational Genomics Research Institute (TGen), have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens.

19 Aug 2020

Combination treatment can benefit children with Kawasaki disease

Adding corticosteroids to standard intravenous (IV) immunoglobulin treatment for children with Kawasaki disease judged to be at higher risk of developing blood vessel complications made initial treatment more successful and prevented these complications.

19 Aug 2020

Conservative therapy program can improve quality of osteoarthritis care

With implementation of conservative treatment methods like physiotherapy and individually tailored, adjusted exercises, quality of osteoarthritis care can improve and patients can delay the need for an artificial hip or knee joint.

19 Aug 2020

Pioneering program empowers stroke survivors during COVID-19 lockdown

A pioneering program to empower people living with complex long-term conditions such as a stroke or multiple trauma manage their own rehabilitation has been kept on the road during the coronavirus pandemic – thanks to an expert from Kingston University and St George’s, University of London taking the service to online.

19 Aug 2020

CARE consortium launches to accelerate drug discovery and development for COVID-19

CARE a new consortium supported by the Innovative Medicines Initiative public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.

19 Aug 2020

Study identifies key gene as future therapeutic target for aggressive endometrial cancer

A new study has identified a key gene in aggressive endometrial cancer, which could lead to a targeted therapeutic strategy to improve survival rates.

19 Aug 2020

Study fills crucial knowledge gaps on myasthenia gravis

A study of 181 patients at 16 sites across the country who test negative for two antibodies long known to cause muscle-weakening myasthenia gravis, found that about 15% test positive for one of two newly discovered antibodies that also attack the point of communication between nerves and muscle.

19 Aug 2020

COVID-19 pandemic delays care for half of breast cancer survivors

The results of an online questionnaire of 609 breast cancer survivors in the U.S. suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic. The study, by researchers at the University of Illinois Chicago, is published in the journal Breast Cancer Research and Treatment.

19 Aug 2020

Gestational hypertension can increase risk of hot flashes during menopause

Women with high blood pressure during pregnancy are at an increased risk for chronic hypertension, diabetes, coronary artery disease, stroke, and early cardiovascular death.

19 Aug 2020

Acidic niche within lymph nodes plays integral role in regulating T cell activation

In the fight against cancer, the immune system is the first line of defense. The lymphatic system specifically is essential to protecting the body against foreign invaders.

19 Aug 2020

Antibody and cellular immunity in severe vs. mild COVID-19

Now, a new study published in the journal Signal Transduction and Targeted Therapy in August 2020 shows that while humoral and T-cell immune responses are more robust in severe infection, the disease activates memory T cells as part of the adaptive immune system in COVID-19 patients irrespective of disease severity.

18 Aug 2020

Study shows how common drug paralyzes the parasites that cause elephantiasis

For years, many scientists and medical professionals likely misunderstood how a commonly prescribed medication for elephantiasis battled the disease, but a new study sets the record straight.

18 Aug 2020

New insights into how high-protein diet protects against fatty liver

Non-alcoholic fatty liver disease is the most common chronic liver disease in the world, with sometimes life-threatening consequences.

18 Aug 2020

Shielding stem cells with novel biomaterial can reduce heart attack damage

Bioengineers and surgeons from Rice University and Baylor College of Medicine (BCM) have shown that shielding stem cells with a novel biomaterial improves the cells' ability to heal heart injuries caused by heart attacks.

18 Aug 2020

New insights into the relationship between stress and pain following TBI

Traumatic brain injury is a leading cause of death and disability. Post-injury distress is common, with many individuals experiencing chronic anxiety and depressive symptoms as well as chronic pain.

18 Aug 2020

Daily cranberry intake could reduce H. pylori infections

A new clinical trial found consuming cranberry juice containing 44 mg of proanthocyanidins (or "PACs") per 240-mL serving twice daily for eight weeks resulted in a 20% reduction in the H. pylori infection rate in Chinese adult participants, when compared to those consuming lower amounts of juice and a placebo.

18 Aug 2020

Calcified plaque in the arteries better predicts future heart attacks than strokes

The amount of calcified plaque in the heart's arteries is a better predictor of future heart attacks than of strokes, with similar findings across sex and racial groups, according to new research from UT Southwestern.

18 Aug 2020

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.

18 Aug 2020